Upgrade

Apimeds Pharmaceuticals US, Inc

APUS

Last
$4.74
Day
-14.0%
1y
-72.7%
5y
-75.0%
52w
-90.8%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1132d
EMA 21
4.59
EMA 50
4.85
EMA 200
10.59
20d high
-44.0%
5y high
-90.8%
5y range
7th
Website · United States

Positions held

Your positions

APUS isn't in your positions.

Add it to see shares, cost, and P&L here.

Score
14
Hold
watch
Signal
Neutral
Target
$9.39
Stop
$2.28
Stop distance
51.9%
Target vs last
+98.1%

Fundamentals

Market cap$8.32MEnterprise value—Trailing P/E—Forward P/E—
PEG—Price / book8.49Beta—Dividend yield0.00%
Revenue growth—Earnings growth—Gross margin0.0%Operating margin0.0%
Profit margin0.0%ROE—ROA—Debt / equity—
Current ratio—Free cash flow—Analyst recommendationnoneMean target—
52w high$59.7052w low$1.51

Quarterly

2026-Q22026-Q12025-Q42025-Q32025-Q22025-Q1
Revenue$0.0M$0.0M$0.0M$0.0M$0.0M—
Op margin——————
Net income-$20.2M-$35.1M-$1.2M-$1.8M-$2.7M—
Gross margin——————
Gross profit——————
Operating income-$6.3M-$12.2M-$7.0M-$1.8M-$2.7M—

Yearly (6y)

20252024202320222021
Revenue$0.0M$0.0M$0.0M$0.0M—
Op margin—————
Net income-$6.0M-$1.4M-$0.8M-$0.7M—
Gross margin—————
Gross profit—————
Operating income-$11.9M-$1.3M-$0.7M-$0.6M—
Headline scan

No flags

• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).

News

APUS · daily+229.9% over 14 sessions
Close EMA21 EMA50 EMA200
1.203.465.737.9910.252026-092026-092026-092026-092026-102026-102026-10
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin
-$35M-$26M-$18M-$9M$0M0%5%10%2025-Q22025-Q32025-Q42026-Q12026-Q2